HUTCHMED (LON:HCM) Stock Crosses Below 200 Day Moving Average - Here's Why

Key Points

• HUTCHMED (LON:HCM) stock fell below its 200-day moving average, which is currently at GBX 231.09 ($3.11), marking a low trade at GBX 229 ($3.08).
• The company's stock is down 2.6%, with a market capitalization of £1.96 billion and a P/E ratio of 430.19.
• HUTCHMED operates a fully integrated R&D platform focused on oncology, with three approved cancer drug candidates now available in China and the U.S.

HUTCHMED (China) Limited (LON:HCM - ) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 231.09 ($3.11) and traded as low as GBX 229 ($3.08). HUTCHMED shares last traded at GBX 236 ($3.17), with a volume of 1,775 shares.

HUTCHMED Stock Down 2.6%

The company has a current ratio of 2.81, a quick ratio of 2.97 and a debt-to-equity ratio of 11.97. The company has a market capitalization of £1.96 billion, a P/E ratio of 430.19 and a beta of 0.76. The stock has a 50 day moving average price of GBX 234.52 and a 200 day moving average price of GBX 231.09.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.